Boyd Street Capital targets $100M for second healthcare growth fund

What's the deal? Boyd Street CapitalDealroom has a profile for this one. Try Dealroom → has launched HealthTech Platform Fund II, a growth capital fund with a $100 million target. The Oklahoma-based firm will back growth-stage healthcare technology companies across AI, digital health, medical devices, diagnostics, healthcare software, and infrastructure.

Who's involved? The firm appointed Lisa Risser as general partner of the fund. Risser will help lead investment strategy and commercialization work while advising portfolio companies and strategic partners.

What's the endgame? The fund is the growth capital engine behind Boyd Street CapitalDealroom has a profile for this one. Try Dealroom →'s broader Mission 2030 strategy to build a globally connected healthcare innovation platform. That platform links research institutions, health systems, founders, industry, family offices, and capital into one commercialization ecosystem.

Why now? "Healthcare is entering one of the most transformative periods in its history," said founder and chief executive officer James Spann. He pointed to the convergence of artificial intelligence, digital health, precision medicine, and new models of care.

Cross-border play: The firm says it is already facilitating cross-border initiatives, bringing technologies developed outside the US into the American market while helping US innovations expand internationally. Target sectors span clinical decision support, virtual care, diagnostics, care delivery, and healthcare data and analytics.

The signal: Boyd Street Capital is betting that capital alone isn't enough. By pairing growth funding with a venture studio, commercialization expertise, and institutional partnerships, it is positioning the fund as an operating platform rather than a passive investor — a model increasingly common as healthtech investors compete on more than cheques.

Image credit: boyd street capital